BriaCell Therapeutics Receives FDA Clearance To Initiate Clinical Evaluation Of Bria-BRES+, Its Next Generation Cell-Based Immunotherapy For Metastatic Breast Cancer

BriaCell Therapeutics Corp

BriaCell Therapeutics Corp

BCTX

0.00
  • FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinical study for Bria-BRES+ in metastatic breast cancer
  • Bria-BRES+ is BriaCell's next generation personalized immunotherapy for breast cancer, and features additional immune activating components designed to enhance clinical efficacy
  • BriaCell has prepared clinical supplies of Bria-BRES+ and plans to initiate a Phase 1/2a clinical study in metastatic breast cancer in the coming months
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.